Session 9 – Biotech Business Models and Financing Strategy
Date: 23 July (Thursday) 15:40 – 17:10 (GMT+8)
Venue: 701EF, 7F, TaiNEX2 / Online event platform
Dr. Ji Li has more than 20 years of business development, R&D and investment experience in the biopharmaceutical sector. He is currently Venture Partner at Lilly Asia Ventures (LAV), one of the most successful healthcare venture firms from China. Prior to LAV, Ji was Executive VP and Global Head of Business Development at BeiGene where he oversees the company’s partnering activities worldwide, including leading the landmark strategic transaction with Celgene that has transformed BeiGene into a fully integrated biopharmaceutical company. Prior to BeiGene, Ji served as VP of Business Development and Licensing at Merck, where he led the group that was responsible for BD activities of all late-stage inbound and outbound partnering opportunities globally. During this period, Ji has also served, on behalf of Merck, as member of the Board of Director for BeiGene. Prior to Merck, Ji was Executive Licensing Director, External R&D at Amgen where he led the company’s product search and evaluation BD team. Earlier in his career, Dr. Li was key member of the Amgen research team discovered and validated the RANKL signaling pathway that has led to the successful development and commercialization of Denosumab, the current standard of care therapy for various bone loss indications with annual sales of more than $4 billion. Ji obtained his B.S. in Pharmacology from Shanghai Medical University and Ph.D. in Neuroscience from Mount Sinai School of Medicine in New York.
Speech title & Synopsis
The important role of partnering and collaboration to build value in the biopharmaceutical industry will be illustrated with three diverse deal examples.